Skip to main content

Health condition · Clinically reviewed

Kaposi sarcoma, HHV-8, ART and modern tumour-directed care.

A vascular tumour driven by human herpesvirus 8. Classic, endemic, transplant-related and AIDS-related forms each need a slightly different plan, built around a specialist MDT.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against BHIVA, NCCN and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance on HHV-8 driven disease, ART-first care and pomalidomide for AIDS-related KS.

Key facts

Kaposi sarcoma at a glance.

The essentials, in plain English. What it is, the four main forms and the levers that change outcomes.

  • What it is

    An angioproliferative vascular tumour caused by human herpesvirus 8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus (KSHV).

  • Classic KS

    Mediterranean and Eastern European elderly men, indolent lower-limb plaques and nodules.

  • Endemic KS

    Sub-Saharan African form, often aggressive with lymphadenopathy and generalised skin disease.

  • Iatrogenic KS

    Linked to immunosuppression, particularly after solid-organ transplantation. Specialist commissioned care.

  • Epidemic KS

    AIDS-related, the most common form worldwide. Skin, oral, GI, pulmonary and lymphatic involvement possible.

  • First-line lever

    Antiretroviral therapy for HIV drives regression in most AIDS-related cases before any tumour-directed treatment.

Why this guide matters

One virus, four faces, a shared plan.

Kaposi sarcoma is uncommon and often unfamiliar to patients when they receive the diagnosis. These three points shape the rest of this guide.

  • HHV-8 is the driver

    Every form of KS is linked to human herpesvirus 8. Immunity, not exposure alone, decides who develops disease.

  • ART changes AIDS-related KS

    For patients living with HIV, sustained antiretroviral therapy is the single most powerful intervention.

  • Modern systemic care works

    Liposomal doxorubicin, pomalidomide and, in selected cases, checkpoint inhibitors give real options in advanced disease.

How the diagnosis is made

From first lesion to a clear plan.

The steps a UK HIV physician, dermatologist or oncologist will normally follow, in order, so you know what to expect and why.

  1. 01

    Assessing

    History and risk review

    HIV status, immunosuppression, transplant history, travel and country of origin all shape the likely subtype.

  2. 02

    Assessing

    Full skin and oral examination

    Reddish-purple, brown or violaceous papules, plaques and nodules, plus palate and gum lesions and regional lymphadenopathy.

  3. 03

    Assessing

    HIV testing and CD4

    HIV test, CD4 count and viral load are essential in every new case. Specialist HIV commissioned pathways apply.

  4. 04

    Confirming

    Skin biopsy with HHV-8 IHC

    Punch biopsy of a representative lesion with immunohistochemistry for HHV-8 latent nuclear antigen (LANA) confirms the diagnosis. Specialist commissioned dermatopathology.

  5. 05

    Confirming

    Staging imaging

    CT of the chest, abdomen and pelvis, with PET-CT and endoscopy where visceral disease is suspected. Specialist commissioned.

  6. 06

    Preparing

    MDT review

    Joint HIV, oncology, dermatology and radiotherapy discussion. Specialist commissioned multidisciplinary planning.

  7. 07

    Preparing

    Baseline for systemic therapy

    Cardiac assessment, bloods and performance status before liposomal anthracyclines, taxanes or newer agents.

Typical timeline: first suspected lesion to an MDT plan in a few weeks.

Symptoms

What Kaposi sarcoma actually looks like.

Skin lesions are the classic picture, but mouth, gut, chest and lymphatic involvement each carry their own signs. Any of these deserves specialist attention.

  • Cutaneous plaques and nodules

    Reddish-purple, brown or violaceous papules, plaques and firm nodules, most often on the legs, feet or face.

  • Mucosal lesions

    Palate, gums and oral cavity lesions, sometimes the first sign of disease. Can bleed or interfere with eating.

  • Lymphoedema

    Woody swelling of the legs, feet or genitals from lymphatic involvement. See our guide to lymphoedema compression care.

  • Gastrointestinal disease

    Often silent, sometimes causing occult bleeding, iron-deficiency anaemia, pain or obstruction.

  • Pulmonary involvement

    Dyspnoea, cough, haemoptysis or pleural effusions. Can mimic infection in advanced HIV.

  • Lymphadenopathy

    Localised or generalised nodal disease, particularly in the endemic African form.

  • Systemic symptoms

    Weight loss, fever and night sweats, especially in aggressive AIDS-related or endemic disease.

  • Red flag features

    Rapid progression, visceral symptoms, oedema at presentation or bulky mucosal disease need urgent specialist review.

Treatment

How Kaposi sarcoma is treated in the UK.

Treatment is chosen from a ladder that starts with ART or reduced immunosuppression, moves through local and radiotherapy options and, when needed, adds systemic and immunotherapy agents. Every step is specialist commissioned.

  • Antiretroviral therapy

    ART is the single most effective intervention for AIDS-related KS. Many patients see regression without any tumour-directed therapy. Specialist commissioned HIV care.

  • Local excision or cryotherapy

    Useful for small, isolated or cosmetically troublesome cutaneous lesions. Specialist commissioned dermatology or plastics.

  • Intralesional vinblastine

    Injected directly into cutaneous or oral lesions for localised control. Specialist commissioned.

  • Radiotherapy

    Highly effective for symptomatic skin, oral and lymphoedematous disease. Specialist commissioned clinical oncology.

  • Liposomal doxorubicin

    Pegylated liposomal doxorubicin (Caelyx, Doxil) is the standard first-line systemic agent for advanced KS. See our liposomal doxorubicin clinic.

  • Liposomal daunorubicin or paclitaxel

    Alternative systemic options where anthracyclines are unsuitable or exhausted. Specialist commissioned.

  • Pomalidomide (Pomalyst)

    Approved in 2020 for AIDS-related KS after failure of systemic chemotherapy, and for HIV-negative KS. See our pomalidomide Kaposi sarcoma clinic.

  • Immunotherapy

    Pembrolizumab and nivolumab are emerging options in selected refractory or HIV-negative cases. See our immunotherapy checkpoint clinic.

What this guide is based on

The sources behind every claim on this page.

UK and international guidance current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your HIV physician, dermatologist or oncologist knows your history and can tell you which parts apply to you. If in doubt, get seen.

  • BHIVA. Guidelines for HIV-associated malignancies.

  • NCCN. AIDS-related Kaposi sarcoma guidelines.

  • ESMO. Cutaneous and AIDS-related Kaposi sarcoma clinical practice guidelines.

  • MHRA and NICE. Pomalidomide for Kaposi sarcoma prescribing guidance.

Red flags

When Kaposi sarcoma needs urgent attention.

Most KS is managed as planned MDT care. These are the situations where the timeline shortens sharply.

  • Pulmonary Kaposi sarcoma

    Breathlessness, cough, haemoptysis or pleural effusion in a patient with KS is a medical emergency needing urgent respiratory and oncology input.

  • Gastrointestinal bleeding

    Occult or overt GI bleeding, iron-deficiency anaemia or obstructive symptoms need urgent endoscopy and specialist review.

  • Rapidly progressive skin disease

    Fast-growing, ulcerating or extensive cutaneous disease warrants prompt MDT discussion.

  • Severe lymphoedema

    Painful, disabling lymphoedema needs early compression care alongside tumour-directed treatment.

  • New KS after transplant

    Any new KS lesion in a transplant recipient is a signal to review immunosuppression urgently with the transplant team.

  • Undiagnosed HIV

    A new KS diagnosis should always trigger HIV testing. An undiagnosed HIV infection changes the entire treatment pathway.

  • IRIS after starting ART

    Immune reconstitution inflammatory syndrome can flare KS soon after ART is started. Needs specialist HIV oversight.

  • Bulky oral disease

    Extensive palate or pharyngeal lesions that interfere with eating, speaking or airway need urgent radiotherapy or systemic input.

  • Systemic B symptoms

    Fever, night sweats and weight loss can signal aggressive visceral disease or a coexisting HIV-related lymphoma.

Living with it

A treatable condition, with a clear plan.

Four things that make the biggest difference day to day. Adherence, skin surveillance, lymphoedema care and specialist support.

A quiet reminder

Consistency, not crisis, drives outcomes.

Steady ART, steady clinic contact and steady skin checks are what quietly change the long-term picture.

  1. 01 ART

    Treat HIV first

    For AIDS-related KS, sustained antiretroviral therapy is the foundation of everything else. Adherence directly changes outcomes.

  2. 02 Skin care

    Protect and monitor the skin

    Gentle skin care, photographs of lesions and early reporting of new sites help your team track response and progression.

  3. 03 Oedema

    Manage lymphoedema early

    Compression, elevation and skilled lymphoedema therapy reduce swelling, pain and infection risk. See our lymphoedema compression guide.

  4. 04 Support

    Lean on specialist support

    Terrence Higgins Trust, Macmillan and your HIV and oncology teams offer counselling, financial and practical help.

Frequently asked

Everything we get asked about Kaposi sarcoma.

Quick answers on HHV-8, ART, biopsy, pomalidomide and the outlook for the different forms.

  • What is Kaposi sarcoma?

    Kaposi sarcoma is a vascular tumour caused by human herpesvirus 8 (HHV-8, also called KSHV). It usually starts as reddish-purple or brown patches, plaques or nodules on the skin, and can involve the mouth, lymph nodes, gut and lungs. There are several forms, including classic, endemic African, transplant-related and AIDS-related.

  • Is Kaposi sarcoma always linked to HIV?

    No. AIDS-related KS is the most common form worldwide, but classic KS occurs in older Mediterranean and Eastern European men, endemic KS affects people in parts of sub-Saharan Africa, and iatrogenic KS follows immunosuppression after transplantation. HIV testing is still important in every new case.

  • How is Kaposi sarcoma diagnosed?

    The diagnosis is confirmed by a skin biopsy showing the typical spindle-cell vascular pattern, with immunohistochemistry positive for HHV-8 latent nuclear antigen (LANA). Depending on symptoms, staging includes CT of the chest and abdomen, PET-CT, endoscopy, HIV testing and CD4 count.

  • What is the first treatment for AIDS-related KS?

    Antiretroviral therapy is the single most effective step for AIDS-related KS. Many patients see partial or complete regression on ART alone. Tumour-directed treatment is added when disease is bulky, symptomatic or visceral, or if it does not respond to ART.

  • What is pomalidomide and where does it fit in?

    Pomalidomide (Pomalyst) is an oral immunomodulatory drug approved in 2020 for AIDS-related KS after chemotherapy failure, and for HIV-negative KS. It is prescribed and monitored by specialist teams. Our pomalidomide Kaposi sarcoma clinic explains the pathway in more detail.

  • Can Kaposi sarcoma be cured?

    Outcomes depend on the subtype and extent. Classic KS is often indolent and lived with over many years. AIDS-related KS frequently regresses on ART and responds well to modern chemotherapy and, where appropriate, immunotherapy. Transplant-related KS can improve when immunosuppression is safely reduced. Care is always individualised through a specialist MDT.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.